(NewsDirect)
Emyria Ltd (ASX:EMD)managing director Michael Winlo joins Proactive to discuss thehealthcare stock’s Pax Centre acquisition.
The move brings atop-tier clinical service — specialising in comprehensivepsychological trauma care — into the EMD fold, expanding itscapabilities as it develops a pipeline of MDMA-assistedtherapies.
Winlosays the acquisition will be transformative, strengthening Emyria’sclinical service foundations as it builds a care-centric model fordelivering mental health treatments.
“The acquisition also improves our ability tocollect crucial clinical data that can help engage payers as well asdrive further care model improvements and novel drug development,”he told the market this week.
Pax Centre director Dr Jon Laugharne added:"The prospects of integrating Emyria's data-driven researchapproach with our existing care models is incrediblyexciting.”
“We believe that withEmyria’s support we have an opportunity to become a centre ofexcellence that only offers innovative and cost-effective treatmentsto patients but also helps train and support the next generation ofspecialists and therapists."
ContactDetails
Proactive Investors
JonathanJackson
+61 413 713 744
Jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.